Pt FW Chronic cavitary pulmonary aspergillosis with TB and emphysema

Date: 23 January 2014

  • Chest X Ray 22/12/00

  • Chest X Ray 27/02/01

Prev
Next

A 43 year old with smoking related emphysema was admitted to hospital with two separate episodes of haemoptysis. He had been in good health up to 1989, when he was diagnosed as having bilateral pulmonary tuberculosis. At that time a CT scan revealed a cavity in the left upper lobe (20.8cm2) with adjacent confluent infiltrates and pleural thickening. On bronchoscopic examination no abnormalities were noted and endobronchial biopsies did not reveal hyphae.

Over the next 4 years his condition deteriorated and a CT scan showed the left upper lobe cavity had increased to 40cm2. Itraconazole 400mg daily was prescribed. There was some clinical improvement on itraconazole but patient eventually deteriorated with breathlessness and with significant weight loss.

Copyright: n/a

Notes:

Images library

Showing 10 posts of 2574 posts found.

  • Title

    Legend

  • Haemofungin

    haemofungin

  • E1210 structure

    E1210

  • ABPA and mucoid impaction

    Patient YML ABPA and mucoid impaction Image 1, Patient YML ABPA and mucoid impaction Image 2

  • Patient JSG: Nicotine stained fingers in ABPA with bronchiectasis

    Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.

    Nicotine stained fingers - image 1, Nicotine stained fingers - image 2

  • T-2307

    The chemical structure of the novel arylamidine T-2307

    T2307

  • Laryngeal Aspergillosis, ptSA

    Laryngeal aspergillosis, probably related to inhaled corticosteroids.

    Image A., Image B., Image C., Image D.

  • VL-2397 (ASP2397)

    VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:

    • A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
    • Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
    • Activity against azole-resistant fungal species.
    • Low propensity for P450 drug-drug interactions.

    VL-2397 (ASP2397)

  • SCY-078 (MK-3118)

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor

  • Biafungin acetate

    Biafungin acetate, a new echinocandin

    Biafungin acetate, a new echinocandin

  • Primary Aspergillus pneumonia

    Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010

    Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010